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known intermediate in the highly conserved sterol biosynthetic
pathway. Furthermore, our studies show that compounds that
block the sterol pathway beyond FPP, such as the zaragozic
acids, cause an increase of up to eightfold in intracellular and
extracellular farnesol levels. Significantly, many clinically useful antifungal antibiotics target the ergosterol biosynthetic
pathway. Examples include the allylamines (e.g., terbinafine)
and the azoles (e.g., fluconazole, ketoconazole, and itraconazole). Our results suggest that farnesol accumulation plays a
role in both the antifungal activity exhibited by drugs that
target sterol biosynthesis and some of the idiosyncrasies exhibited by those drugs, e.g., difficulties in obtaining precise MICs
(11).
The conversion of FPP to farnesol was shown by incubating
[1-3H] (E,E)-FPP with a C. albicans cell homogenate in a
modification of the allylpyrophosphatase assay described by
Bansal and Vaidya (1) for rat liver enzymes. C. albicans A72
was grown overnight in yeast extract-peptone-dextrose broth
(8). One milliliter of culture (5 ⫻ 108 cells/ml) was placed in a
1.5-ml microfuge tube, and the cells were collected by centrifugation at 13,000 rpm (unless otherwise stated, all centrifugation was performed with an Eppendorf 5415D centrifuge). The
pellet was resuspended in 100 l of 0.1 M citrate buffer (Na⫹
salt) at pH 5.5, 0.45% Triton X-100, 5 mM EDTA, 25 M
pepstatin A, 25 M leupeptin, and 0.5 mM phenylmethylsulfonyl fluoride. The two chelating agents (5 mM EDTA and 100
mM citrate) inactivate the metal ion-dependent squalene synthase for which FPP could also act as substrate (1). This expectation that squalene would not be produced was confirmed
by thin-layer chromatography (TLC) assay of the product. The
buffered cell suspension was transferred to a 0.5-ml microfuge
tube, and 0.45-mm acid-washed glass beads (0.4 g) were added
to just below the meniscus. The tubes were vortexed at top
speed at 4°C for 6 min. The cell extract was separated from the
beads by forming a hole in the bottom with a hot 25-gauge
needle, placing the 0.5-ml tube in a 1.5-ml tube, and collecting
the buffered cell extract by centrifugation at 13,000 rpm. This
cell extract was diluted 1:20 with fresh citrate-EDTA buffer so
that each assay contained ca. 0.5 mg of protein in 100 l of
solution mixture. The FPP stock contained (per 100 l) 2 g of

Candida albicans is one of the most commonly isolated fungal pathogens of humans. It is a common cause of nosocomial
infections and is the fourth most common cause of all bloodstream infections (6) as well as 31% of all urinary tract infections in intensive care units (4). It is a member of the body’s
normal microbial flora, and it is a medically important opportunistic pathogen—especially for immunocompromised individuals. Candida bloodstream infections, i.e., candidemia, are
also widespread due to chemotherapy, extensive use of antibiotics, indwelling intravenous catheters, and other surgical and
medical manipulations (6). The mortality for candidemia is in
excess of 30%, irrespective of treatment (6), partially because
of a shortage of effective antifungal antibiotics. Furthermore,
those antifungals that do exist are often, for unknown reasons,
very strain dependent and dosage dependent (11). Because of
its medical importance, C. albicans has also become a model
system for fungal molecular biology.
C. albicans can grow as hyphae, pseudohyphae, or budding
yeasts, and the availability of these multiple, interconvertible
morphologies is of great benefit to the organism’s pathogenic
lifestyle. Indeed, monomorphic mutants are typically avirulent
(7). Because of its importance in pathogenicity, yeast-mycelial
dimorphism in C. albicans has been of great interest for a long
time (10). In this regard, we showed that C. albicans produces
(E,E)-farnesol as an extracellular quorum-sensing molecule
which, when it has accumulated above a threshold level, prevents the yeast-to-mycelium conversion and causes the culture
to grow as actively budding yeasts without influencing cellular
growth rates (5). Farnesol has also been found to prevent
biofilm formation by C. albicans (12). Thus, farnesol’s synthesis
and mode of action are of interest because (i) it is the first
eukaryotic quorum-sensing molecule identified, and (ii) it provides a novel target for the development of antifungal drugs
intended to prevent mycelial growth or biofilm production in
C. albicans. The present study shows that C. albicans synthesizes farnesol from farnesyl pyrophosphate (FPP), a well* Corresponding author. Mailing address: School of Biological Sciences, University of Nebraska, Lincoln, NE 68588-0666. Phone: (402)
472-2253. Fax: (402) 472-8722. E-mail: knickerson1@unl.edu.
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The dimorphic fungus Candida albicans produces farnesol as a quorum-sensing molecule that regulates
cellular morphology. The biosynthetic origin of farnesol has been resolved by treating these cells with zaragozic
acid B, a potent inhibitor of squalene synthase in the sterol biosynthetic pathway. Treatment with zaragozic
acid B leads to an eightfold increase in the amount of farnesol produced by C. albicans. Furthermore, C.
albicans cell extracts contain enzymatic activity to convert [3H]farnesyl pyrophosphate to [3H]farnesol. Many
common antifungal antibiotics (e.g., zaragozic acids, azoles, and allylamines) target steps in sterol biosynthesis. We suggest that the fungicidal activity of zaragozic acid derives in large part from the accumulation of
farnesol that accompanies the inhibition of sterol biosynthesis.
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(E,E)-FPP (Sigma, St. Louis, Mo.) and 0.09 g of [3H](E,E)FPP (American Radiolabeled Chemicals, Inc., St. Louis, Mo.)
in distilled water. To remove any non-FPP impurities present,
15-l portions of the FPP stock were spotted on a glass-backed
silica TLC plate and developed by using a mobile phase of
ethyl acetate-hexane solution (1:4). The FPP, being hydrophilic, will not move from the baseline. The baseline area was
scraped and added directly to the cell extract. The final concentration of FPP was 0.45 Ci/0.31 g/100 l. The reaction
was run at 37°C by using an Eppendorf Thermostat 5320 heating block. To stop the reaction, 0.5 ml of 100% hexane was
added. The tubes were vortexed for 2 min and, to achieve a
clean phase separation, centrifuged at 13,000 rpm for 1 min.
Samples (200 l) were removed from the top layer, placed in
2 ml of scintillation fluid, and counted in a Beckman LS1701
scintillation counter. TLC (ethyl acetate-hexane, 1:4) confirmed that the radioactivity detected was due to labeled farnesol. Counts per minute were measured at Rf values from 0 to
0.1 (FPP Rf ⫽ 0), 0.35 to 0.55 (farnesol Rf ⫽ 0.45), and 0.65 to
1 (squalene Rf ⫽ 0.87). No radioactivity was detected at Rf
from 0 to 0.1 or 0.65 to 1. Furthermore, autoradiograms of the
TLC plates confirmed that the FPP was converted to farnesol.
All of the radioactivity that had left the origin was confined to
a single spot whose migration coincided exactly with that of
authentic [1-3H](E,E)-farnesol (American Radiolabeled
Chemicals, Inc.). Figure 1 shows a time course for the conversion of FPP to farnesol by C. albicans cell extracts. The reaction was linear over the first 30 min, and ca. 8% of the FPP had
been converted to farnesol at that time. No farnesol was made
by heated (95°C for 10 min) cell extracts. Thus, C. albicans
possesses the enzymatic machinery to convert FPP to farnesol.
Recognition that farnesol is made from FPP suggests that
cell perturbations that elevate the FPP pool size should also
elevate farnesol production levels. As a case in point: treatment of mice (15), rats, or dogs (3) with zaragozic acid, a

potent inhibitor of squalene synthase, leads to greatly increased production of farnesoic acid and the farnesol-derived
dicarboxylic acids as excretion products in urine. C. albicans
A72 was grown for 24 h at 30°C in 100 ml of glucose-phosphate-proline (5) with 0 to 0.5 M zaragozic acid B, generously
supplied by Merck. The zaragozic acid B stock (1 mM in water)
was wrapped in aluminum foil and stored at 4°C. The cells
were harvested by centrifugation in a Beckman J-21C centrifuge at 15,300 ⫻ g for 5 min. The cell pellets were washed once
in distilled water, and dry weights were determined by using
preweighed planchets and baking the samples in an oven at
180°C for 1 h. The farnesol-containing supernatants were filter
sterilized (0.22-m-pore-size Whatman filters) and extracted
with 1/4 volume ethyl acetate. The ethyl acetate was removed
under reduced pressure (Yamato RE-47) with mild heat
(30°C), whereupon the dried samples were resuspended in 1 ml
of 20% ethyl acetate-hexane and transferred to a 2-ml vial. The
solvent was again removed under reduced pressure at 30°C,
and then the samples were resuspended in 50 l of 20% ethyl
acetate-hexane solution. One microliter was used for farnesol
determination by gas chromatography-mass spectroscopy as
previously described by Hornby et al. (5). The resulting doseresponse curve is shown in Fig. 2. The levels of farnesol excreted increased eightfold in a roughly linear, dose-dependent
fashion, reaching a maximum of ca. 1 mg of farnesol per g of
cell dry weight at a 0.5 M concentration of zaragozic acid B.
By using a broth dilution method based on growth within 18 h
in glucose-phosphate-proline medium (5), the MIC of zaragozic acid B for C. albicans A72 was ca. 0.5 M. The levels of
intracellular farnesol also increased in a proportional manner
(data not shown).
It is reasonable to expect that farnesol accumulation will
contribute to the antifungal activity of sterol-blocking drugs
such as zaragozic acid. As an example, 25 M farnesol inhibits
growth of the budding yeast Saccharomyces cerevisiae (9). The
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FIG. 1. Time course for conversion of FPP to farnesol by C. albicans cell extracts. Each point is the average of at least two separate experiments.
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inhibitory effect of farnesol is thought to act by arresting the
cell cycle (9) and inducing reactive oxygen species in the yeast
mitochondria (8). Also, in higher organisms, excess farnesol
has been reported to inhibit Ca2⫹ channels (13) and induce
apoptosis (16). However, for C. albicans, concentrations of up
to 250 M farnesol in one study (5) and 300 M in another
study (12) caused no inhibition of growth rate by itself. It is
possible that farnesol becomes more inhibitory when ergosterol synthesis is blocked. Odds (11) suggested that some of the
inhibitory effects of the azoles are caused by their insertion into
the membrane of ergosterol-deprived cells. Due to farnesol’s
lipophilicity, it is likely that it would do the same.
Our basic thesis is that farnesol accumulation contributes to
the antifungal activity of zaragozic acid and may be a common
theme for other antibiotics that block sterol biosynthesis. That
is, the overall mode of action of these inhibitors is not based
simply upon their ability to deplete fungal cells of ergosterol
(11). This idea is supported by several previous observations
and comments. Taylor et al. (14) showed that the azoles were
still inhibitory toward sterol auxotrophic mutants of S. cerevisiae. Odds (11) also states, “most azoles are able to prevent or
greatly perturb hyphal growth of C. albicans. The drugs retard
or annul the initial outgrowth of germ tubes and entirely prevent hyphal branching, thus leading to cultures of largely or
entirely yeast-form cells, even on media that normally support
development of long hyphae.” When we combine the accumulation of farnesol in response to sterol inhibition (Fig. 2) and
farnesol’s known ability to block hyphal development in C.
albicans (5), these observations are the expected result.
The remainder of our discussion will concern fungal MICs.
Sterol biosynthetic inhibitors such as the azole antifungals
“tend not to give clear MIC end points: they cause partial
inhibition of fungal growth over a wide range of concentrations, sometimes even giving sigmoid dose-response curves”
(11). Odds also documents the wide variability of MIC results

for the azoles, often greater than 100-fold, as being due to
variations in the inoculum size, pH and composition of the
growth medium, incubation time, cation concentration, and
incubation temperature (11). Additionally, we observed variability in determining MICs for zaragozic acid B depending on
whether the experiments used 25- or 250-ml Erlenmeyer flasks.
Prior to this study, there have been no reports of MICs for the
zaragozic acids against whole cells of C. albicans. Earlier studies have shown MICs for these inhibitors against S. cerevisiae
and Ki values for the target enzyme, squalene synthase (2). A
possible reason for this is the ineffectiveness of the zaragozic
acids in a clinical setting. These compounds readily bind to
serum components, rendering them unavailable in the bloodstream (2). At the time of their discovery, it was thought
surprising that the zaragozic acids were fungicidal rather than
fungistatic (2). We now suggest that the fungicidal nature of
zaragozic acid derives in part from the accumulation of farnesol, which accompanies the inhibition of ergosterol biosynthesis. Furthermore, we predict that other antifungals that block
carbon flow through the sterol biosynthetic pathway will cause
C. albicans to secrete elevated levels of farnesol, which might
also contribute to their toxicity.
We thank Sara Basiaga for her assistance with gas chromatographymass spectroscopy and Merck and Co., Inc., Rahway, N.J., for the
zaragozic acid B used in this study.
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